Determining preclinical-stage candidate value can be challenging, but when the principal developer is also an early-stage “platform company” (ESPC), with a complex value proposition, that valuation can become even more difficult.
Read MoreWith both 2016 and another JPM behind us, several key issues/events/trends will affect our industry in the coming weeks and months. Few have drawn as much attention from such array of constituents as drug pricing.
Read More